NCT00762346View on ClinicalTrials.gov

Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis

PHASE4CompletedINTERVENTIONAL
Enrollment

156

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

March 31, 2013

Study Completion Date

March 31, 2013

Conditions
Non Small Cell Lung CancerBone MetastasesHigh NTX Level
Interventions
DRUG

zometa

zometa 4mg i.v. every 4 weeks for up to 2 years

Trial Locations (1)

510080

cancer center, Sun Yat-sen University, Guangzhou

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Sun Yat-sen University

OTHER